Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hengli botulinum toxin type A for lower-limb spasticity in children with spastic cerebral palsy
CTR20220925Phase 3Completed
- Sponsor
- Lanzhou Biotechnology Development
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lanbotulinumtoxin-A in cerebral palsy (CP), Muscle spasm, sponsored by Lanzhou Biotechnology Development. Started May 2022; status: completed.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
cerebral palsy (CP)Muscle spasm
Beyond the preview
Go deeper on CTR20220925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220925.